Go to Health Care Provider version
| Diagnosis | Anaplastic Wilms Tumor, Recurrent Wilms Tumor | Study Status | Open |
| Phase | II |
| Age | up to 30 Years | Randomisation | NO |
| Line of treatment | First line treatment, Disease relapse or progression |
| Routes of Treatment Administration | Chemotherapy medications, all given intravenously (Carboplatin, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Topotecan, Vincristine)
|
| Last Posted Update | 2024-04-30 |
| ClinicalTrials.gov # | NCT04322318 |
International Sponsor
Children's Oncology GroupPrincipal Investigators for Canadian Sites
Alberta Children's Hospital - Dr. Victor Lewis
BC Children's Hospital - Dr. David Dix
CancerCare Manitoba - Dr. Ashley Chopek
McMaster Children's Hospital - Dr. Uma Athale
Stollery Children's Hospital - Dr. Sarah McKillop
Western Children's Hospital - Dr. Shayna Zelcer
Children's Hospital of Eastern Ontario (CHEO) - Dr. Donna Johnston
Hospital for Sick Children - Dr. Daniel Morgenstern
Montreal Children's Hospital - Dr. Sharon Abish
CHU Quebec - Dr. Bruno Michon
CHU Ste. Justine - Dr. Yvan Samson
IWK Health Centre - Dr. Craig Erker
Janeway Hospital - Dr. Lisa Goodyear
CHU Sherbrooke - Dr. Josée BrossardCentres
Medical contact
Rebecca Deyell
Social worker/patient navigator contact
Ilana Katz
Clinical research contact
Hem/Onc/BMT Clinical Trials Unit
Medical contact
Dr. Magimairajan Vanan
Social worker/patient navigator contact
Rhéanne Bisson
Clinical research contact
Rebekah Hiebert
Megan Ridler
Kathy Hjalmarsson
Medical contact
Dr. Carol Portwine
Social worker/patient navigator contact
Jane Cassano
Clinical research contact
Sabrina Millson
Medical contact
Dr. Donna Johnston
Dr. Lesleigh Abbott
Dr. Doaa Abdel Fattah
Social worker/patient navigator contact
Sherley Telisma
Clinical research contact
Carol Duchenne
Medical contact
Dr. Alexandra Zorzi
Dr. Shayna Zelcer
Social worker/patient navigator contact
Cindy Milne Wren
Jessica Mackenzie Harris
Clinical research contact
Mariam Mikhail
Medical contact
Clinical Research Unit
Social worker/patient navigator contact
Clinical Research Unit
Clinical research contact
Stephanie Badour
Medical contact
Dr. Victor Lewis
Social worker/patient navigator contact
Wendy Pelletier
Clinical research contact
Debra Rich
Medical contact
Raoul Santiago
Social worker/patient navigator contact
Isabelle Audet
Clinical research contact
Barbara Desbiens
Medical contact
Dr. Sarah McKillop
Dr. Sunil Desai
Social worker/patient navigator contact
Danielle Sikora
Michelle Woytiuk
Jaime Hobbs
Clinical research contact
Amanda Perreault
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
Social worker/patient navigator contact
Marie-Claude Charrette
Clinical research contact
Marie Saint-Jacques
Medical contact
Dr. Paul Moorehead
Social worker/patient navigator contact
Stephanie Eason
Clinical research contact
Bev Mitchell
Medical contact
Dr. Josee Brossard
Social worker/patient navigator contact
Please Contact Site Directly
Clinical research contact
Please Contact Site Directly
Study Description
In this study, researchers want to find out if
- they can improve treatment for participants with newly diagnosed diffuse anaplastic Wilms tumour (DAWT). In hopes of finding a better therapy to fight against the cancer, participants will be given chemotherapy drugs and radiation therapy in this study. The chemotherapy drugs that participants will be receiving are often given to fight against cancer and together, the treatment is known as Regimen UH-3. This study looks at how well Regimen UH-3 works when given to children and young adults with newly diagnosed DAWT.
- they can improve treatment for participants with "standard risk" favourable histogy Wilms tumour (FWHT) that has come back (relapsed). In hopes of finding a better therapy to fight against the cancer, participants will be given chemotherapy drugs and radiation therapy in this study. The chemotherapy drugs that participants will be receiving are often given to fight against cancer and together, the treatment is known as Regimen UH-3. This study looks at how well Regimen UH-3 works when given to children and young adults with "standard risk" favourable histogy Wilms tumour (FWHT) that has come back (relapsed).
- they can improve treatment for participants with "high-risk or very high-risk" favourable histogy Wilms tumour (FWHT) that has come back (relapsed). In hopes of finding a better therapy to fight against the cancer you have, participants will be given chemotherapy drugs and radiation therapy in this study. The chemotherapy drugs that participants will be receiving are often given to fight cancer and together, the regimen is known as Regimen ICE/Cyclo/Topo. This study looks at how well this regimen works when given to children and young adults with "high-risk or very high-risk" favourable histogy Wilms tumour (FWHT) that has come back (relapsed).
Drugs used in chemotherapy regimens work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Inclusion Criteria
- Age less than 30 years
- New diagnosis of diffuse anaplastic Wilms tumour
- OR a diagnosis of Wilms tumour at first relapse (tumour that has come back, and must have been "favourable histology" at initial diagnosis)
- Patient must be capable of all self care - such that they are out of bed >50% of day
- Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team
